$PGNY

Livingston Mark S. sold $7K of PGNY

Livingston Mark S. (CHIEF FINANCIAL OFFICER) sold 279 shares of Progyny, Inc. (PGNY) at $26.20 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Livingston Mark S.
Published Jun 3, 2026, 8:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGNY
Neutral
medium confidence
Mentioned
$PGNY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

This disclosure provides incremental information about insider liquidity, but the article contains no new operational or financial developments for Progyny.

02

Market read

Traders may treat it as low-signal unless paired with other insider activity or fundamental catalysts.

03

What to watch

Consider whether there are concurrent insider buys/sales in recent filings and whether the sale size is unusual relative to prior Form 4 activity.

Relevance 6/10Novelty 3/10Timing: Filed June 3; transaction dated June 2

Background

SEC Form 4 reports insider transactions (officers/directors/10% owners). A 10b5-1 plan indicates sales were pre-scheduled to reduce timing-based trading concerns.

Company-level read

Ticker impact

$PGNYNeutralMedium confidence
Context

Progyny CFO Livingston Mark sold 279 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely minimal, with any effect more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction with an explicit pre-arranged 10b5-1 plan; no earnings, guidance, or operational change is cited.

Market effects

No direct sector read-through; this is company-specific insider activity without new business information.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with management views on valuation; monitor for follow-on selling or changes in sale cadence.

Key entities

  • Progyny, Inc.

    Company whose CFO disclosed an open-market sale of shares under a pre-arranged 10b5-1 plan.

  • Livingston Mark S.

    Chief Financial Officer who sold 279 shares on June 2, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

$PGNYMedAI 8/10

Q2 Earnings Outperformers: Cencora (NYSE:COR) And The Rest Of The Health Insurance Providers Stocks

Cencora (COR) is down 6.7% since reporting Q2 earnings, trading at $97.38. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, dropping 14.1% to $25.94. Humana (HUM) reported $40.87B revenue, up 26.2% YoY, beating estimates, and rose 5% to $407.96. Cigna (CI) reported $71.56B revenue, up 6.6% YoY, beating estimates, but fell 4% to $284.64.

$PGNYMed

Progyny at Wells Fargo healthcare conference: growth runway stays wide

Progyny (PGNY) presented at the Wells Fargo Healthcare Conference, noting seasonal August softness but expecting a September recovery. The company serves 7.2M lives, with a large addressable market. It adjusted 2024 guidance downward but emphasized long-term growth, new product lines, and strong cash flow. Management highlighted Progyny's leading position in fertility benefits and expansion into women's health. The stock is trading below its Fair Value, with a PEG ratio of 0.46, according to Inv

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.